21:41 , May 29, 2019 |  BC Extra  |  Company News

May 29 Company Quick Takes: Priority Review for Amarin's Vascepa; plus Tuhura-Moffitt Cancer Center deal and more

Priority Review for Vascepa to reduce CV risk  Amarin Corp. plc (NASDAQ:AMRN) gained $1.98 (12%) to $18.99 on Wednesday after FDA accepted and granted Priority Review to an sNDA for Vascepa icosapent ethyl to reduce...
13:35 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Amarin's Vascepa reduces total CV events by 30% in REDUCE-IT

Amarin reported additional data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) showing that the drug led to a 30% reduction in total CV events vs....
04:32 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Amarin raises $200M ahead of Vascepa push

Amarin Corp. plc (NASDAQ:AMRN) raised $200 million on Nov. 26 in a follow-on as it prepares to add cardioprotective data to the label of omega-3 therapy Vascepa icosapent ethyl following a readout from the Phase...
18:57 , Nov 27, 2018 |  BC Extra  |  Financial News

Amarin raises $200M ahead of Vascepa push

Amarin Corp. plc (NASDAQ:AMRN) raised $200 million in a follow-on late Monday as it prepares to add cardioprotective data to the label of omega-3 therapy Vascepa icosapent ethyl following a readout from the Phase III...
16:04 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Amarin details primary endpoint data for Vascepa, addresses placebo concern

Amarin Corp. plc. (NASDAQ:AMRN) presented detailed primary endpoint data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) and addressed concerns that the mineral oil used in...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
18:16 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Phase III data for Amarin's Vascepa link triglycerides to CV risk

Amarin Corp. plc. (NASDAQ:AMRN) reported top-line data from the Phase III REDUCE-IT trial showing that once-daily 4 g Vascepa icosapent ethyl led to a 25% reduction in major adverse cardiovascular events (MACE) vs. placebo, meeting...
23:03 , Sep 24, 2018 |  BC Extra  |  Clinical News

Amarin gains 315% after data link triglycerides with CV risk

Amarin Corp. plc. (NASDAQ:AMRN) jumped $9.41 (315%) to $12.40 on Monday after top-line data from the Phase III REDUCE-IT trial showed that once-daily 4 g Vascepa icosapent ethyl led to a 25% reduction in major...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...